BONADE: FOCUS ON ETHINYL ESTRADIOL AND DIENOGEST


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

In order to assess suitability of the combined oral contraceptive Bonade to requirements and expectations of women, publications included in the Cochrane Library, EMBASE, PUBMED, MEDLINE, eLIBRARY.RU databases and free access electronic databases were analyzed using key words. The results of this analysis allow to consider Bonade as a reliable contraceptive drug with minimal content of hormone and modern gestogen, which provides a minimum of side effects and high control of the menstrual cycle. There were also non-contraceptive effects of the drug in respect of hyperandrogenic dermopathy and symptoms of endometriosis. These characteristics allow to recommend Bonade as an effective alternative for women due to improving the quality of life and economic efficiency.

全文:

受限制的访问

作者简介

G. Dikke

Email: galadikke@yandex.ru
Honored Worker of Science and Education, MD, Prof. at the Department of Obstetrics, Gynecology and Reproductive Medicine of the Faculty of Continuing Medical Education FSAEI HPE «Peoples' Friendship University of the Russia» of the Russian Ministry of Education Moscow

参考

  1. Bahamondes L., Bahamondes M.V. New and emerging contraceptives: a state-of-the-art review. !nt. J. Womens Health. 2014;6:221-34.
  2. Method mix. USAID. MEASURE Evaluation Population and Reproductive Health (PRH). 2014. Retrieved from http:// www.cpc.unc.edu/.
  3. Mackenzie H., Draho A., Pallikadavath S., Stone W., et al. What is the Impact of Contraceptive Methods and Mixes of Contraceptive Methods on Contraceptive Prevalence, Unmet Need for Family Planning, and, Unwanted and Unintended Pregnancies? An Overview of Systematic Reviews. 2011. Retrieved from http://r4d.dfid.gov.uk/.
  4. Perez-Campos E.F. Ethinylestradiol/Dienogest in Oral Contraception. Drugs. 2010; 70(6):681-89.
  5. Ziller M., Rashed A.N., Ziller V., Kostev K. The prescribing of contraceptives for adolescents in German gynecologic practices in 2007 and 2011: a retrospective database analysis. J. Pediatr. Adolesc. Gynecol. 2013; 26(5):261-64.
  6. Kovacs, L., Hoffmann H. A new low-dose oral contraceptive containing ethinylestradiol, estradiol and dienogest: first experience of its clinical use. !n: M. Elstein, Ed. Extragenital Effects of Oral Contraceptives. New York, 1997. P. 39-44.
  7. Kuhl H. Ideal dose of ethinylestradiol. !n: Elstein M., Ed. Extragenital Effects of Oral Contraceptives. New York, 1997. P. 27-38.
  8. Moore C., Carol W., Graser T., et al. Influence of dienogest on ovulation in young fertile women. Clin. Drug Invest. 1999;18:271-78.
  9. Sitruk-Ware R. Pharmacological profile of pro-gestins. Maturitas. 2004;47:277-83.
  10. Oettel M., Holz C. Hybrid progestins - The example of dienogest. In: Sitruc-Ware R., Mishell D. Eds. Progestins and Antiprogestins in Clinical Practice. New York, 2000. P. 163-78.
  11. Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric. 2003;6:17-23.
  12. Benagiano G., Carrara S., Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Prefer Adherence. 2009;3:131-43.
  13. Oettel M., Carol W., Elger W., et al. A 19-nor-progestin without a 17a-ethinyl group. Il: Dienogest from a pharmacodynamic point of view. Drugs of Today. 1995;31:517-36.
  14. Oettel M., Carol W., Graser T., et al. Der Einflub einer Ethinylestradiol-Dienogest-Kombination auf die Serum-Androgen-Konzentrationen. Zentralbl Gynakol. 1997;119:597-606.
  15. Oettel M., Breitbarth H., Elger W. The pharmacological profile of dienogest. Eur. J. Contracept. Reprod Health Care. 1998;3:1-12.
  16. Oettel M., Graser T., Hoffmann H., et al. The preclinical and clinical profile of dienogest. A short overview. Drugs of Today. 1999; 35(Suppl. C):3-12.
  17. Moore C., Luderschmidt C., Moltz L., et al. Antiandrogenic properties of the dienogest-con-taining oral contraceptive Valette (tm). Drugs of Today. 1999;35(C):69-78.
  18. Elger W., Beier S., Pollow K., Garfield R., Shi S.Q., Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003; 68:891-905.
  19. Schoonen W.G., Deckers G., de Gooijer M.E., de Ries R., Mathijssen-Mommers G., Hamersma H., Kloosterboer H.J. Contraceptive progestins. Various 11-substituents combined with four 17-substituents: 17alpha-ethynyl, five- and six-membered spiromethylene ethers or six-membered spiromethylene lactones. J. Steroid Biochem Mol. Biol. 2000;74(3):109-23.
  20. Golbs S., Domhardt R., Presl J., Ganev M., Wisser K.H., Zimmermann T. Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in Czech Republic. Meth Find Exptl. Clin. Pharmacol. 2002;24(10):689-96.
  21. Golbs S., Domhardt R., Radowicky S., Kaluzny Z., Wisser K.H., Zimmermann T. Clinical findings with the oral contraceptive combination ethinylestradiol/dienogest in Poland. Methods Find Exp. Clin. Pharmacol. 2002;24(9):585-92.
  22. Zimmermann T., Dietrich H., Wisser K.-H., Hoffmann H. Efficacy and tolerability of the dienogest-containing oral contraceptive Valette (tm). Results of a postmarketing surveillance study. Drugs of Today. 1999;35(C):79-87.
  23. Kaunitz A.M., Portman D., Westhoff C.L., Ar-cher D.F., Mishell D.R. Jr, Rubin A., Foegh M. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial. Obstet. Gynecol. 2014;123(2 Pt 1):295-303.
  24. Alan Guttmacher Institute, Facts in Brief, First Year Contraceptive Failure Rates. Retrieved May 10, 2005. http://www.agi-usa.org/pubs/fb_ contr_use.html
  25. Brill K., Norpoth T., Schnitker J., Albring M. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users. Contraception. 1991;43:101-10.
  26. Corson S.L. Contraceptive efficacy of a mono-phasic oral contraceptive containing desogestrel. Am. J. Obstet. Gynecol. 1993;168:1017-20.
  27. Archer D. Clinical and metabolic features of desogestrel: A new oral contraceptive preparation. Am. J. Obstet. Gynecol. 1994; 170:1550-55.
  28. Runnebaum B., Grunwald K., Rabe T. The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate / 35 μg of ethinyl estradiol): Results of an open, multicenter study of 59,701 women. Am. J. Obstet. Gynecol. 1992;166:1963-69.
  29. Wiegratz I., Lee J.H., Kutschera E., Bauer H.H., von Hayn C., Moore C., Mellinger U., Winkler U.H., Gross W., Kuhl H. Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception. 2002;65:223-29.
  30. Wiegratz I., Stahlberg S., Manthey T., Sanger N., Mittmann K., Palombo-Kinne E., Mellinger U., Lange E., Kuhl H. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on lipid metabolism during 1 year of conventional or extended-cycle use. Contraception. 2010;81(1):57-61.
  31. Godsland I.F., Crook D., Simpson R., Proudler T., Felton C., Lees B., Anyaoku V., Devenport M., Wynn V. The effect of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N. Engl. J. Med. 1990;323:1375-81.
  32. Kuhl H., Marz W., Jung-Hoffmann C., Heidt F., Gross W. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. Am. J. Obstet. Gynecol. 1990;163:363-69.
  33. Wiegratz I., Stahlberg S., Manthey T., Sanger N., Mittmann K., Palombo-Kinne E., Mellinger U., Lange E., Kuhl H. Effects of combined oral contraceptive ethinylestradiol (30 microg) and dienogest (2 mg) on carbohydrate metabolism during 1 year of conventional or extended-cycle use. Horm. Metab. Res. 2010;42(5):358-63.
  34. Jandrain B.J., Humblet D.M., Jaminet C.B., Scheen A.J., Gaspard U.J., Lefebvre P.J. Effects of ethinyl estradiol combined with desogestrel and cyproterone acetate on glucose tolerance and insulin response to an oral glucose load: A one-year randomized, prospective, comparative trial. Am. J. Obstet. Gynecol. 1990; 163:378-81.
  35. Wiegratz I., Stahlberg S., Manthey T., Sanger N., Mittmann K., Lange E., Mellinger U., Kuhl H. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception. 2008;78(5):384-91.
  36. Wiegratz I., Lee J.H., Kutschera E., Winkler U.H. Kuhl H. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97-106.
  37. Dinger J., Assmann A., Möhner S., Minh T.D. Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control study. J. Fam. Plann. Reprod. Health Care. 2010;36(3):123-29.
  38. Rekers H. Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel. Acta Obstet. Gynecol Scand. 1988;67:171-74.
  39. Fuchs N, Duesterberg B, Weber-Diehl F., Mühe B. The effect on blood pressure of a monophasic oral contraceptive containing ethinylestra diol and gestodene. Contraception. 1995; 51:335-39.
  40. Moore C., Feichtinger W., Klinger G., et al. Clinical findings with the dienogest-containing oral contraceptive Valette (tm). Drugs of Today. 1999;35(C):53-68.
  41. Монахов С.А., Иванов О.Л., Самгин М.А. Антиандрогенные препараты: современная терапия акне у женщин. Гинекология. 2005;5:11.
  42. Zimmermann T., Wisser K-H., Dietrich H. Effects of the dienogest-containing oral contraceptive Valette (tm)on skin and hair. Results of a post-marketing surveillance study. Drugs of Today. 1999;35(C):97-104.
  43. Palombo-Kinne E., Schellschmidt I., Schumacher U., Graser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception. 2009;79(4):282-89.
  44. Raudrant D., Rabe T. Progestogens with anti-androgenic properties. Drugs. 2003;63(5): 463-92.
  45. Burrows L.J., Basha M., Goldstein A.T. The effects of hormonal contraceptives on female sexuality: A review. J. Sex. Med. 2012; 9:2213-23.
  46. Strowitzki T., Faustmann T., Gerlinger C., Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: A 12-week, randomized, double-blind, placebo-controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010;151(2):193-98.
  47. Gallagher E.J., Liebman M., Bijur P.E. Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann. Emerg Med. 2001;38(6):633-38.
  48. Barbieri R.L. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am. J. Obstet. Gynecol. 1992;166:740-45.
  49. Cosson M., Querleu D., Donnez J., Madelenat P., Konincks P., Audebert A., Manhes H. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: Results of a prospective, multicenter, randomized study. Fertil Steril. 2002;77(4):684-92.
  50. Strowitzki T., Marr J., Gerlinger C., Faustmann T., Seitz C. Dienogest is as effective as leupro-lide acetate in treating the painful symptoms of endometriosis: A 24-week, randomized, multicentre, open-label trial. Hum. Reprod. 2010;25(3):633-41.
  51. Del Pup L. If the aim is ovarian cancer prevention and estrogen mediated benefits, not only endometriosis suppression, are contraceptives with ethinilestradiol better than progestogens alone? WCRJ 2014;1(3):e273. http://www.wcrj.net/
  52. Vercellini P., Crosignani P., Somigliana E., Vigano P., Frattaruolo M.P., Fedele L. Waiting for Godot: a commonsense approach to the medical treatment of endometriosis Hum. Reprod. 2011;26(1):3-13.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##